Growing out of the old self: management itself says the company has quietly become a different business, and the numbers
The model's full reasoning — Q4 2017 call → NOThe question asks whether management conveys that the company is now running on a different basis than its reported results and reputation were built on — that is, a change of basis already real, and management says the record and perception lag the change. Let me examine the transcript for evidence. Key points from the call: - Dave Stack discusses the opioid epidemic and EXPAREL's role. - They discuss partnerships with J&J, CMS reimbursement efforts, clinical trials, etc. - Charlie Reinhart gives financial results and guidance for 2018. Now, does management describe the company as having crossed into a different kind of business? Let me look for specific language. Dave Stack says: "we are expanding the use of EXPAREL through three strategic pillars: first, generating level one clinical data and key surgical procedures; second, driving education and awareness around the need for opioid-sparing solutions; and third, partnering with those who share our commitment to reducing the role of the operating room as the gateway to opioid use and abuse." This is about strategy, not a change of basis. He discusses CMS reimbursement: "We are currently working with CMS policymakers to achieve an off-cycle change around reimbursement practices that bundle EXPAREL within their fixed payment to outpatient and ambulatory surgical centers." This is a future opportunity, not yet realized. He says: "Securing separate reimbursement for EXPAREL would create a significant opportunity for us." — future tense. Regarding guidance, Charlie says: "we are guiding to total EXPAREL net product sales of between $300 million and $310 million in 2018. This range aligns with our 2017 year-over-year average daily growth rates recorded during each quarter, ranging from 6% to 10%." This is ordinary guidance. Dave Stack on guidance: "we have not done a good job over the last couple of years of making sure that we've met the guidance that we put out there, so we wanted to be appropriately conservative." This is about guidance conservatism, not a change of basis. Is there any statement that the company is now a different kind of business? The company is still selling EXPAREL, still a pharmaceutical company. The partnerships, clinical trials, and reimbursement efforts are all part of the same business model.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| SANG | Sangoma Technologies Corporation | Q2 2024 | 2024-02-08 | D |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| CALX | Calix, Inc. | Q1 2023 | 2023-04-20 | C+ |
| WD | Walker & Dunlop, Inc. | Q2 2022 | 2022-08-09 | C+ |
| KD | Kyndryl Holdings, Inc. | Q4 2021 | 2022-03-01 | C+ |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
| CAG | Conagra Brands, Inc. | Q2 2017 | 2016-12-22 | C+ |
CALX · Q1 2023 → YESThe question is whether management conveys that the company today is running on a different basis than what its reported results and reputation were built on. Both parts: a change of basis already rea...YES The transcript shows management describing the company as now operating on a fundamentally different basis—selling into a new market of broadband service providers building consolidated networks, shifting from a legacy cyclical model to sequential revenue through platforms, clouds, and managed services—while treating this as an accomplished reality today, not a future plan. They emphasize numbers like 988 BSP deployments, 865 cloud customers, and 334 managed services customers, along with three years of over 25% growth, as evidence of this new foundation already in place.
SANG · Q2 2024 → YESThe question is whether management conveys that the company today is running on a different basis than the one its reported results and reputation were built on. Both parts: a real change of basis alr...
WD · Q2 2022 → YESThe question is whether management conveys that the company today is running on a different basis than the company its reported results and reputation were built on. Specifically, two parts: a change ...